AlphaStocks
5.2
Consider Buy

HALOZYME THERAPEUTICS, INC. (HALO)

Health Care / Biotechnology

S&P MidCap 400

$65.44

Below average on several measures. Research carefully.

Consider Buy

Score based on 5 of 5 models — high confidence

#511out of 1127 in Health Care

Is HALOZYME THERAPEUTICS, INC. a Good Investment in 2026?

HALOZYME THERAPEUTICS, INC. (HALO) scores 5.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates HALOZYME THERAPEUTICS, INC. as Attractive (5/9). However, the Graham model rates it Caution — Significantly above fair value. HALOZYME THERAPEUTICS, INC. currently trades below its estimated fair value of $79, suggesting potential upside. HALOZYME THERAPEUTICS, INC. ranks #511 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E25.6ROE113.4Market Cap8B

Estimated Fair Value

$79.3017% below

Fair value above market price. ROE of 113% signals strong profitability.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 0.7 · Fast Grower

Greenblatt

Neutral

Top 25% (rank 15%)

Frequently Asked Questions

Is HALOZYME THERAPEUTICS, INC. (HALO) a good investment?
Based on AlphaStocks' composite analysis, HALOZYME THERAPEUTICS, INC. (HALO) scores 5.2 out of 10, earning a Consider Buy rating. This score is below average, suggesting caution. Fair value above market price. ROE of 113% signals strong profitability.
What is HALOZYME THERAPEUTICS, INC.'s Piotroski F-Score?
HALOZYME THERAPEUTICS, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is HALO overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $79, HALO appears undervalued. The stock currently trades 17% below its estimated fair value. Fair value above market price. ROE of 113% signals strong profitability.
How does HALO compare to other Health Care stocks?
HALOZYME THERAPEUTICS, INC. ranks #511 out of 1127 stocks in the Health Care sector, placing it in the top 45% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about HALO?
AlphaStocks evaluates HALO using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 5.2/10.

Similar Stocks

PARRFTIAZN

Compare HALO with

HALO vs PARRHALO vs FTIHALO vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer